JR Urology Ltd 09481956 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is medical consultancy. Digita Accounts Production Advanced 6.30.9574.0 true 09481956 2024-04-01 2025-03-31 09481956 2025-03-31 09481956 core:RetainedEarningsAccumulatedLosses 2025-03-31 09481956 core:ShareCapital 2025-03-31 09481956 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 09481956 bus:SmallEntities 2024-04-01 2025-03-31 09481956 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 09481956 bus:FullAccounts 2024-04-01 2025-03-31 09481956 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 09481956 bus:RegisteredOffice 2024-04-01 2025-03-31 09481956 bus:Director1 2024-04-01 2025-03-31 09481956 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 09481956 core:OfficeEquipment 2024-04-01 2025-03-31 09481956 countries:EnglandWales 2024-04-01 2025-03-31 09481956 2023-04-01 2024-03-31 09481956 2024-03-31 09481956 core:RetainedEarningsAccumulatedLosses 2024-03-31 09481956 core:ShareCapital 2024-03-31 09481956 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 iso4217:GBP xbrli:pure

Registration number: 09481956

JR Urology Ltd

Annual Report and Unaudited Filleted Abridged Financial Statements

for the Year Ended 31 March 2025

 

JR Urology Ltd

Contents

Abridged Balance Sheet

1 to 2

Notes to the Unaudited Abridged Financial Statements

3 to 5

 

JR Urology Ltd

(Registration number: 09481956)
Abridged Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

703

-

Current assets

 

Debtors

-

32,500

Investments

5

5

5

Other financial assets

4

556,340

503,039

Cash at bank and in hand

 

328,997

282,535

 

885,342

818,079

Creditors: Amounts falling due within one year

(12,024)

(25,182)

Net current assets

 

873,318

792,897

Total assets less current liabilities

 

874,021

792,897

Provisions for liabilities

(26,949)

(26,786)

Net assets

 

847,072

766,111

Capital and reserves

 

Called up share capital

400

400

Profit and loss account

846,672

765,711

Total equity

 

847,072

766,111

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

JR Urology Ltd

(Registration number: 09481956)
Abridged Balance Sheet as at 31 March 2025

Approved and authorised by the director on 1 December 2025
 

Dr J Rees

Director

 

JR Urology Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Calyx House
South Road
Taunton
Somerset
TA1 3DU

These financial statements were authorised for issue by the director on 1 December 2025.

2

Accounting policies

Statement of compliance

These abridged financial statements were prepared in accordance with Financial Reporting Standard 102 Section 1A 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover represents the amounts, excluding value added tax, derived from the provision of goods and services to customers during the year.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

JR Urology Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

20% Straight line

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 4 (2024 - 4).

 

JR Urology Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

4

Other financial assets (current and non-current)

Total
£

Current financial assets

Cost or valuation

At 1 April 2024

503,039

Fair value adjustments

14,792

Additions

152,974

Disposals

(113,968)

Transfers

(497)

At 31 March 2025

556,340

Carrying amount

At 31 March 2025

556,340

5

Current asset investments

2025
£

2024
£

Other investments

5

5